These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32315869)

  • 21. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simić D; Skride A; Tang W; Trusz-Gluza M; Vesely J
    J Thromb Thrombolysis; 2021 Nov; 52(4):1195-1206. PubMed ID: 33929686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation.
    Vinding NE; Butt JH; Olesen JB; Xian Y; Kristensen SL; Rørth R; Bonde AN; Gundlund A; Yafasova A; Weeke PE; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    J Am Heart Assoc; 2022 Mar; 11(6):e024402. PubMed ID: 35229642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients.
    Kooistra HA; Piersma-Wichers M; Kluin-Nelemans HC; Veeger NJ; Meijer K
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):388-94. PubMed ID: 27329860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Direct Oral Anticoagulant and Associated Bleeding and Thrombotic Complication after Lower Extremity Bypass.
    Sutzko DC; Kim GY; Novak Z; Bamezai S; Beaulieu RJ; Henke PK; Osborne NH; Beck AW; Obi AT
    J Am Coll Surg; 2022 Nov; 235(5):778-786. PubMed ID: 36102567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism.
    Keita I; Aubin-Auger I; Lalanne C; Aubert JP; Chassany O; Duracinsky M; Mahé I
    Patient Prefer Adherence; 2017; 11():1625-1634. PubMed ID: 29026288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: A real-world patient population.
    de Heide J; de Wit A; Bhagwandien RE; Assaf A; Gros-Bisdom J; van der Meer KC; Wijchers SA; Zijlstra F; Szili-Torok T; Lenzen MJ; Yap SC
    Int J Cardiol; 2021 Mar; 326():98-102. PubMed ID: 33144120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study.
    Bartoli-Abdou JK; Patel JP; Vadher B; Brown A; Roberts LN; Patel RK; Arya R; Auyeung V
    Thromb Res; 2021 Dec; 208():162-169. PubMed ID: 34801919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is There a Role for Vitamin K Antagonist in the Management of Atrial Fibrillation in 2023?
    Burg MR; Ha ACT
    Curr Cardiol Rep; 2023 May; 25(5):391-399. PubMed ID: 36995540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists.
    Auer E; Frey S; Kaesmacher J; Hakim A; Seiffge DJ; Goeldlin M; Arnold M; Fischer U; Jung S; Meinel TR
    J Neurol; 2019 Sep; 266(9):2263-2272. PubMed ID: 31165232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study.
    Paschke LM; Klimke K; Altiner A; von Stillfried D; Schulz M
    BMC Med; 2020 Aug; 18(1):254. PubMed ID: 32847578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs.
    Poli D; Antonucci E; Vignini E; Martinese L; Testa S; Simioni P; Pengo V; Pignatelli P; Falanga A; Masciocco L; Barcellona D; Ciampa A; Chiarugi P; Paparo C; Ageno W; Palareti G;
    Eur J Intern Med; 2020 Oct; 80():73-77. PubMed ID: 32522446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and meta-analysis.
    Hellfritzsch M; Adelborg K; Damkier P; Paaske Johnsen S; Hallas J; Pottegård A; Grove EL
    Basic Clin Pharmacol Toxicol; 2020 Jan; 126(1):21-31. PubMed ID: 31240841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control.
    Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB
    J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
    Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM
    Res Pract Thromb Haemost; 2020 Jan; 4(1):141-153. PubMed ID: 31989096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns.
    Toorop MMA; van Rein N; Nierman MC; Vermaas HW; Huisman MV; van der Meer FJM; Cannegieter SC; Lijfering WM
    J Thromb Haemost; 2020 Jun; 18(6):1390-1397. PubMed ID: 32170987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.